Henry Skinner - Chief Executive Officer @ AMR Action Fund

Start Free Trial

Pricing

Overview

Number of Current Board & Advisor Roles

CB Rank (Investor)

141,633

Primary Job Title Chief Executive Officer
Primary Organization
AMR Action Fund

Location Boston, Massachusetts, United States
Regions Greater Boston Area, East Coast, New England
Gender Male

Investor Type
obfuscated
obfuscation

LinkedIn View on LinkedIn

Henry Skinner is Chief Executive Officer at AMR Action Fund. Attended Texas A&M University.

Partner Investments

Number of Partner Investments

Announced Date	Organization Name	Investor Name	Lead Investor	Funding Round	Money Raised
obfuscated obfuscation	Centauri Therapeutics	AMR Action Fund	Yes	Series A - Centauri Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Peptilogics	AMR Action Fund	—	Series B - Peptilogics	obfuscated obfuscation
obfuscated obfuscation	TenNor Therapeutics	AMR Action Fund	Yes	Series E - TenNor Therapeutics	obfuscated obfuscation
obfuscated obfuscation	F2G	AMR Action Fund	Yes	Series H - F2G	obfuscated obfuscation
obfuscated obfuscation	Elion Therapeutics	AMR Action Fund	Yes	Series B - Elion Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Antabio	AMR Action Fund	—	Series B - Antabio	obfuscated obfuscation
obfuscated obfuscation	Venatorx Pharmaceuticals	AMR Action Fund	Yes	Series C - Venatorx Pharmaceuticals	obfuscated obfuscation
obfuscated obfuscation	Adaptive Phage Therapeutics	AMR Action Fund	Yes	Series B - Adaptive Phage Therapeutics	obfuscated obfuscation
obfuscated obfuscation	Oculis	Tekla Capital Management	—	Series C - Oculis	obfuscated obfuscation
obfuscated obfuscation	Priothera	Tekla Capital Management	Yes	Series A - Priothera	obfuscated obfuscation

Jobs

Number of Current Jobs

Number of Past Jobs

Henry Skinner

is the

Chief Executive Officer

AMR Action Fund

. Additionally,

Henry Skinner

has had

past jobs including

Managing Director Novartis Venture Funds

Novartis

AMR Action Fund Chief Executive OfficerMar 2021

Organization Name	Title At Company	Start Date	End Date
Novartis	Managing Director Novartis Venture Funds	Nov 2008	2017
Pfizer	Senior Director	Oct 1999	Aug 2003
Pharmacia	Director Technology Acquisitions	1997	2001
FORMA Therapeutics	Team Member	—	—
Cylene Pharmaceuticals	Team Member	—	—
NeoGenesis Pharmaceuticals	CEO	—	—
Novartis Venture Fund	Managing Director	2011	—
Merus	Team Member	—	—
SelectX Pharmaceuticals Inc.	CEO	—	—

Board and Advisor Roles

Number of Current Board & Advisor Roles

Henry Skinner

holds

board and advisor roles including

Board Member

Priothera

Board Member

HotSpot Therapeutics

, and

Advisor

Dynacure

Priothera Board MemberOct 2020
HotSpot Therapeutics Board MemberMay 21, 2020
Dynacure AdvisorApr 2, 2020
Galera Therapeutics Board of Directors
CuraSen Therapeutics Board Of directors
Thesan Pharmaceuticals Board of Directors
AMP Therapeutics Board Member
NeuroVia Board Of Directors
Zikani Therapeutics Chairman of the Board
Oculis Board of Directors

Related Hubs

Hub Name	CB Rank (Hub)
Early Stage Venture Investors with Investments in Massachusetts	4,277
Post IPO Investors with Investments in East Coast	22,940
Female Founded Early Stage Venture Investors with Investments in Greater Boston Area	52,331
Female Founded Late Stage Venture Investors with Investments in United States	39,078
Massachusetts Post IPO Investors	87,053
East Coast Female Founded Venture Capital Investors	51,267
Female Founded Late Stage Venture Investors with Investments in Boston, Massachusetts	63,390
Boston Post IPO Investors	93,020
Greater Boston Area Female Founded Investors	88,106
Late Stage Venture Investors with Investments in Boston, Massachusetts	8,493

Education

Henry Skinner

studied at

University of Illinois Urbana-Champaign

Worcester Polytechnic Institute

, and

University of Illinois Urbana-Champaign

University of Illinois Urbana-Champaign Ph.DMicrobiology
Worcester Polytechnic Institute BSBiology & Biotechnology
University of Illinois Urbana-Champaign MSBiochemistry
Baylor College of Medicine Post DoctoralHuman and Molecular Genetics1997